Abstract | AIM: PATIENTS AND METHODS: The files of 14 children treated at our hospital between 2005 and 2010 with the diagnoses of relapsed brain tumors were reviewed for pathological characteristics, treatment results, and outcomes. RESULTS: The median age at relapse was 8 years (range, 1.08-23; F/M, 5/9). Diagnoses included medulloblastoma (n = 5), atypical teratoid rhabdoid tumor (n = 2), ependymoma (n = 2), glioneuronal tumor (n = 1), malignant neoplasm (n = 1), pontine glioma (n = 1), astrocytoma grade III (n = 1), and glioblastoma multiforme (n = 1). All patients except the one with pontine glioma had undergone surgical resection, and all had prior adjuvant chemotherapy. Twelve out of 14 patients had received radiotherapy. The median number of temozolomide courses was 5.0 (range, 1-24). Objective response rate in our patients was 35.7% (three complete responses, one partial response, and one minor response). Stable disease achieved in 14.3% of patients and 50% had progressive disease. Median survival time was 8 months (range, 1-55). At the end of the study, three patients were alive. Hematological toxicity was seen in 30.8% of all courses. CONCLUSIONS:
|
Authors | Canan Akyüz, Haci Ahmet Demir, Ali Varan, Bilgehan Yalçin, Tezer Kutluk, Münevver Büyükpamukçu |
Journal | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
(Childs Nerv Syst)
Vol. 28
Issue 1
Pg. 111-5
(Jan 2012)
ISSN: 1433-0350 [Electronic] Germany |
PMID | 21866330
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Adolescent
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Brain Neoplasms
(drug therapy)
- Child
- Child, Preschool
- Dacarbazine
(analogs & derivatives, therapeutic use)
- Female
- Humans
- Infant
- Male
- Neoplasm Recurrence, Local
(drug therapy)
- Retrospective Studies
- Temozolomide
- Young Adult
|